Optiscan Imaging (ASX:OIL) Debt-to-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Optiscan Imaging Debt-to-Asset?

Optiscan Imaging's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.22 Mil. Optiscan Imaging's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.00 Mil. Optiscan Imaging's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was A$15.63 Mil. Optiscan Imaging's debt to asset for the quarter that ended in Jun. 2024 was 0.01.

Optiscan Imaging Debt-to-Asset Historical Data

The historical data trend for Optiscan Imaging's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optiscan Imaging Debt-to-Asset Chart

Optiscan Imaging Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.06

0.07

0.09

0.01

Optiscan Imaging Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.07	0.09	0.09	0.03	0.01

Competitive Comparison of Optiscan Imaging's Debt-to-Asset

For the Scientific & Technical Instruments subindustry, Optiscan Imaging's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Optiscan Imaging's Debt-to-Asset Distribution in the Hardware Industry

For the Hardware industry and Technology sector, Optiscan Imaging's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Optiscan Imaging's Debt-to-Asset falls into.

Optiscan Imaging Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Optiscan Imaging's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.221	+	0)	/	15.63
	=	0.01

Optiscan Imaging's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.221	+	0)	/	15.63
	=	0.01

Optiscan Imaging (ASX:OIL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Optiscan Imaging Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Optiscan Imaging's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Optiscan Imaging Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Optiscan Imaging Ltd (ASX:OIL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Miles Street, Mulgrave, Melbourne, VIC, AUS, 3170

Website

https://www.optiscan.com

Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.